Marinus Pharma (MRNS) Plans Public Offering of Common Stock and Concurrent Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Marinus Pharma (MRNS) Announces Elan Ezickson to Board
December 12, 2019 7:31 AM ESTMarinus Pharmaceuticals, Inc. (NASDAQ: MRNS) announced today that Elan Ezickson, has joined the Companys Board of Directors. Mr. Ezickson is a highly accomplished executive with over 30 years of experience in the life sciences industry across commercial, operational and strategic... More
Marinus Pharma (MRNS) Prices 28M Share Common Offering at $1.25/Sh; Announces Concurrent Private Placement
December 11, 2019 9:15 AM ESTMarinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced the pricing of an underwritten public offering of 28,000,000 shares of common stock at a public offering price of $1.25 per share. The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters... More
